Filter By
Search
-
FIRST-HALF 2023 SALES OF €5.6 M, DOWN 13 % ON S1 2022, AND CASH POSITION OF €4.3 M
EVRY, FRANCE, THURSDAY JULY 13TH 2023, 7:30 AM - IntegraGen (FR0010908723 - ALINT - PEA eligible...
-
FIRST-HALF 2023 RESULTS - SALES DOWN 13% AND RESILIENT PROFITABILITY
Evry, France, Thursday October 19, 2023, 5:45 pm - IntegraGen (FR0010908723 - ALINT - PEA PME eligible), a...
-
ANNOUNCEMENT OF THE AVAILABILITY OF THE INFORMATION MEMORANDUM AND THE DOCUMENT "OTHER INFORMATION CONCERNING THE LEGAL, FINANCIAL AND ACCOUNTING CHARACTERISTICS" OF ONCODNA S.A.
This press release has been prepared and issued by OncoDNA S.A. pursuant to...
-
COMBINED GENERAL MEETING
IntegraGen's Combined Ordinary and Extraordinary General Meeting will be held on September 17 at 2 pm...
-
AGREEMENT ON A FRIENDLY TAKEOVER BID BY ONCODNA FOR INTEGRAGEN
Agreement to a friendly takeover bid initiated by ONCODNA for INTEGRAGEN at a price...
-
INTEGRAGEN - S1 2020 SALES OF €4.7M UP +13 % AND CASH POSITION OF €5.8M
IntegraGen today announces its unaudited sales figures for the first half of 2020. The sales...
-
INTEGRAGEN - ANNUAL RESULTS 2019
Sales growth (+201TP3Q), EBITDA positive in the second half and close to...
-
INTEGRAGEN ANNOUNCES AN AGREEMENT WITH A LEADING US CANCER CENTER FOR THE USE OF MERCURY™, THE ONCOLOGY SEQUENCING DATA INTERPRETATION AND REPORTING TOOL
IntegraGen announced today that the Dana Farber Cancer Institute will use MERCURYTM, IntegraGen's proprietary software, to...
-
INTEGRAGEN RENEWS PARTNERSHIP AGREEMENT WITH INSTITUT PASTEUR FOR HIGH THROUGHPUT SEQUENCING IN MICROBIOLOGY
IntegraGen today announced the renewal, until December 2021, of its partnership agreement with the Institut Pasteur...
